Aminopeptidases
Methionyl Aminopeptidases
Leucyl Aminopeptidase
Glutamyl Aminopeptidase
Antigens, CD13
Cystinyl Aminopeptidase
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Substrate Specificity
Protease Inhibitors
Cathepsin C
Pyroglutamyl-Peptidase I
Amino Acid Sequence
Molecular Sequence Data
Peptide Hydrolases
Metalloproteases
Enkephalin, Leucine
Digestive System
Aeromonas
Neprilysin
Endopeptidases
Dipeptidyl Peptidase 4
Peptides
Hemolysin Proteins
Antigen Presentation
Amino Acids
Metals
Cloning, Molecular
Drug Design
Sequence Alignment
Endotoxins
Zinc
Histocompatibility Antigens Class I
Cations, Divalent
Binding Sites
Models, Molecular
Sequence Homology, Amino Acid
Cytosol
Hydrogen-Ion Concentration
MedlinePlus
Serine Proteases
Mutation
Seizures
Kidney aminopeptidase A and hypertension, part I: spontaneously hypertensive rats. (1/1462)
Tissue and plasma levels of aminopeptidase A (APA), the principal enzyme that hydrolyzes angiotensin II (Ang II) to angiotensin III, were measured in spontaneously hypertensive rats (SHR) and their normotensive control strain at 3 different ages corresponding to prehypertensive (4 weeks), developing (8 weeks), and established (16 weeks) phases of hypertension. Plasma APA activity was significantly but modestly elevated in SHR at all 3 ages compared with normotensive Wistar-Kyoto rats. Likewise, levels of APA in brain, heart, and adrenal gland were generally, but again only moderately, elevated in SHR at all ages. However, a large increase in APA activity was seen within the kidney in which APA levels were elevated 41%, 51%, and 68% in SHR at 4, 8, and 16 weeks of age, respectively. Kidney APA levels were also significantly increased in immunoblots from 8- and 16-week-old SHR. Glomeruli isolated from 16-week-old SHR had 57% higher APA activity and increased immunoreactivity compared with Wistar-Kyoto rats. To determine whether the increase in kidney APA activity in SHR was related to Ang II levels, SHR were treated for 2 weeks with the angiotensin-converting enzyme inhibitor captopril. Captopril treatment reduced blood pressure to normotensive values and resulted in a 25% reduction in kidney APA activity. These results suggest that APA expression in the kidney may be regulated by activity of the renin-angiotensin system. If so, this would further suggest that upregulation of APA during conditions in which Ang II levels were elevated would have a protective effect against Ang II-mediated cardiovascular diseases, whereas a decrease in APA expression or a failure to upregulate would exacerbate such conditions. (+info)Kidney aminopeptidase A and hypertension, part II: effects of angiotensin II. (2/1462)
Aminopeptidase A (APA) is the principal enzyme that metabolizes angiotensin II (Ang II) to angiotensin III. Previously, we showed that kidney APA was elevated in spontaneously hypertensive rats and was reduced after angiotensin-converting enzyme inhibition. In the present study, we sought to determine whether kidney APA expression was altered after chronically elevated Ang II, either exogenously delivered via osmotic minipumps or endogenously produced in two-kidney, one clip (2K1C) hypertensive rats. Ang II (200 ng. kg-1. min-1) was infused subcutaneously for 1 or 2 weeks by osmotic minipumps, and 2K1C rats were tested 4 weeks after unilateral renal artery clipping. Blood pressure was not significantly elevated in the Ang II-infused animals but was significantly increased at 3 and 4 weeks in the 2K1C animals. APA was significantly elevated approximately 2-fold in kidney cortical membranes from Ang II-infused animals but was decreased 45% in the clipped kidney and 18% in the nonclipped kidneys from 2K1C animals. Isolated glomeruli from Ang II-infused animals and the nonclipped kidneys from 2K1C animals had markedly higher APA activity and immunoreactivity. Likewise, histochemical and immunohistochemical studies indicated that APA levels were increased in glomeruli from angiotensin-infused animals and in both nonclipped and clipped kidneys from 2K1C animals. In contrast, tubular APA was decreased in tubular elements from 2K1C animals, most markedly in the clipped kidneys. Thus, despite the increase in glomerular APA expression in kidneys from 2K1C animals, the decrease in tubular APA expression is more extensive and accounts for the measured reduction in total APA in cortical homogenates. Because clipped kidneys are not exposed to high blood pressure, these results suggest that glomerular APA expression is positively regulated and tubular APA negatively regulated by Ang II. These results further suggest that changes in kidney APA expression could influence the progression of angiotensin-dependent hypertension. (+info)Co-expression of glutathione S-transferase with methionine aminopeptidase: a system of producing enriched N-terminal processed proteins in Escherichia coli. (3/1462)
We describe here an Escherichia coli expression system that produces recombinant proteins enriched in the N-terminal processed form, by using glutathione S-transferase cGSTM1-1 and rGSTT1-1 as models, where c and r refer to chick and rat respectively. Approximately 90% of the cGSTM1-1 or rGSTT1-1 overexpressed in E. coli under the control of a phoA promoter retained the initiator methionine residue that was absent from the mature isoenzymes isolated from tissues. The amount of initiator methionine was decreased to 40% of the expressed cGSTM1-1 when the isoenzyme was co-expressed with an exogenous methionine aminopeptidase gene under the control of a separate phoA promoter. The recombinant proteins expressed were mainly methionine aminopeptidase. The yield of cGSTM1-1 was decreased to 10% of that expressed in the absence of the exogenous methionine aminopeptidase gene. By replacing the phoA with its natural promoter, the expression of methionine aminopeptidase decreased drastically. The yield of the co-expressed cGSTM1-1 was approx. 60% of that in the absence of the exogenous methionine aminopeptidase gene; approx. 65% of the initiator methionine residues were removed from the enzyme. Under similar conditions, N-terminal processing was observed in approx. 70% of the recombinant rGSTT1-1 expressed. By increasing the concentration of phosphate in the growth medium, the amount of initiator methionine on cGSTM1-1 was decreased to 14% of the overexpressed isoenzymes, whereas no further improvement could be observed for rGSTT1-1. The initiator methionine residue does not affect the enzymic activities of either cGSTM1-1 or rGSTT1-1. However, the epoxidase activity and the 4-nitrobenzyl chloride-conjugating activity of the purified recombinant rGSTT1-1 are markedly higher that those reported recently for the same isoenzyme isolated from rat livers. (+info)Endothelin stimulates glucose uptake and GLUT4 translocation via activation of endothelin ETA receptor in 3T3-L1 adipocytes. (4/1462)
Endothelin-1 (ET-1) is a 21-amino acid peptide that binds to G-protein-coupled receptors to evoke biological responses. This report studies the effect of ET-1 on regulating glucose transport in 3T3-L1 adipocytes. ET-1, but not angiotensin II, stimulated glucose uptake in a dose-dependent manner with an EC50 value of 0.29 nM and a 2.47-fold stimulation at 100 nM. ET-1 stimulated glucose uptake in differentiated 3T3-L1 cells but had no effect in undifferentiated cells, although ET-1 stimulated phosphatidylinositol hydrolysis to a similar degree in both. The 3T3-L1 cells expressed approximately 560,000 sites/cell of ETA receptor, which was not altered during differentiation. Western blot analysis and immunofluorescence staining show that ET-1 stimulated the translocation of insulin-responsive aminopeptidase and GLUT4 to the plasma membrane. The effect of ET-1 on glucose uptake was blocked by A-216546, an antagonist selective for the ETA receptor. ET-1 treatment did not induce phosphorylation of insulin receptor beta-subunit, insulin receptor substrate-1, or Akt but stimulated the tyrosyl phosphorylation of a 75-kDa protein. Genistein (100 microM), an inhibitor of tyrosine kinases, inhibited ET-1-stimulated glucose uptake. Our results show that ET-1 stimulates GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes via activation of ETA receptor. (+info)Identification of kallidin degrading enzymes in the isolated perfused rat heart. (5/1462)
Kallidin (KD) is an important vasoactive kinin whose physiological effects are strongly dependent on its degradation through local kininases. In the present study, we examined the spectrum of these enzymes and their contribution to KD degradation in isolated perfused rat hearts. By inhibiting angiotensin-converting enzyme (ACE), aminopeptidase M (APM) and neutral endopeptidase (NEP) with ramiprilat (0.25 microM), amastatin (40 microM) and phosphoramidon (1 microM), respectively, relative kininase activities were obtained. APM (44%) and ACE (35%) are the main KD degrading enzymes in rat heart; NEP (7%) plays a minor role. A participation of carboxypeptidase N (CPN) could not be found. (+info)Hydrolysis of alphas1- and beta-casein-derived peptides with a broad specificity aminopeptidase and proline specific aminopeptidases from Lactococcus lactis subsp. cremoris AM2. (6/1462)
Aminopeptidase hydrolysis of alpha(s)1 - and beta-casein-derived synthetic peptides containing non-consecutive and consecutive proline residues was characterised. Aminopeptidase P (Pep P) (EC 3.4.11.9) or post-proline dipeptidyl aminopeptidase (PPDA) (EC 3.4.14.5) along with lysine-paranitroanilide hydrolase (KpNA-H) (EC 3.4.11.1) activities are required in the degradation of peptides containing non-consecutive proline residues. However, both Pep P and PPDA along with KpNA-H are required for hydrolysis of peptides containing consecutive proline residues. The results demonstrate the mechanism by which combinations of purified general and proline specific aminopeptidases from Lactococcus lactis subsp. cremoris AM2 hydrolyse peptides containing proline residues. (+info)Cloning and functional expression of the cytoplasmic form of rat aminopeptidase P. (7/1462)
A rat cytoplasmic aminopeptidase P was purified from liver cytosol with a procedure including an affinity elution step with 3 microM inositol 1,3,4-trisphosphate. Proteolytic fragments were generated, sequenced and the enzyme was cloned from a rat liver cDNA library. The structure shows high (87.8% and 95.5%, respectively) sequence identity at the nucleotide and amino acid levels with the previously described human putative cytoplasmic aminopeptidase P. The cloned rat enzyme was functionally expressed in Escherichia coli and also in COS-1 cells. Western blot analysis, using an antibody generated against the recombinant protein, and Northern blot hybridization showed ubiquitous expression of the protein in different tissues with the highest expression level in the testis. (+info)Ligand recognition and domain structure of Vps10p, a vacuolar protein sorting receptor in Saccharomyces cerevisiae. (8/1462)
Vp10p is a receptor that sorts several different vacuolar proteins by cycling between a late Golgi compartment and the endosome. The cytoplasmic tail of Vps10p is necessary for the recycling, whereas the lumenal domain is predicted to interact with the soluble ligands. We have studied ligand binding to Vps10p by introducing deletions in the lumenal region. This region contains two domains with homology to each other. Domain 2 binds carboxypeptidase Y (CPY), proteinase A (PrA) and hybrids of these proteases with invertase. Moreover, we show that aminopeptidase Y (APY) is a ligand of Vps10p. The native proteases compete for binding to domain 2. Binding of CPY(156)-invertase or PrA(137)-invertase, on the other hand, do not interfere with binding of CPY to Vps10p. Furthermore, the Q24RPL27 sequence known to be important for vacuolar sorting of CPY, is of little importance in the Vps10p-dependent sorting of CPY-invertase. Apparently, domain 2 contains two different binding sites; one for APY, CPY and PrA, and one for CPY-invertase and PrA-invertase. The latter interaction seems not to be sequence specific, and we suggest that an unfolded structure in these ligands is recognized by Vps10p. (+info)There are many different types of seizures, each with its own unique set of symptoms. Some common types of seizures include:
1. Generalized seizures: These seizures affect both sides of the brain and can cause a range of symptoms, including convulsions, loss of consciousness, and muscle stiffness.
2. Focal seizures: These seizures affect only one part of the brain and can cause more specific symptoms, such as weakness or numbness in a limb, or changes in sensation or vision.
3. Tonic-clonic seizures: These seizures are also known as grand mal seizures and can cause convulsions, loss of consciousness, and muscle stiffness.
4. Absence seizures: These seizures are also known as petit mal seizures and can cause a brief loss of consciousness or staring spell.
5. Myoclonic seizures: These seizures can cause sudden, brief muscle jerks or twitches.
6. Atonic seizures: These seizures can cause a sudden loss of muscle tone, which can lead to falls or drops.
7. Lennox-Gastaut syndrome: This is a rare and severe form of epilepsy that can cause multiple types of seizures, including tonic, atonic, and myoclonic seizures.
Seizures can be diagnosed through a combination of medical history, physical examination, and diagnostic tests such as electroencephalography (EEG) or imaging studies. Treatment for seizures usually involves anticonvulsant medications, but in some cases, surgery or other interventions may be necessary.
Overall, seizures are a complex and multifaceted symptom that can have a significant impact on an individual's quality of life. It is important to seek medical attention if you or someone you know is experiencing seizures, as early diagnosis and treatment can help to improve outcomes and reduce the risk of complications.
Aminopeptidase
Tripeptide aminopeptidase
Aminopeptidase III
Pyroglutamate aminopeptidase
Aminopeptidase I
Alanine aminopeptidase
Aminopeptidase Ey
Clostridial aminopeptidase
Aminopeptidase Y
Tryptophan aminopeptidase
Tryptophanyl aminopeptidase
Aminopeptidase S
Prolyl aminopeptidase
Aspartyl aminopeptidase
Leucyl aminopeptidase
Proline aminopeptidase
Methionyl aminopeptidase
PepB aminopeptidase
Aminopeptidase B
Glutamyl aminopeptidase
Beta-peptidyl aminopeptidase
Dipeptidyl aminopeptidase III
X-Trp aminopeptidase
Xaa-Pro aminopeptidase
D-stereospecific aminopeptidase
Bacterial leucyl aminopeptidase
Cytosol alanyl aminopeptidase
Dipeptidyl peptidase-4
DPP9
Protein metabolism
Leucine aminopeptidase - urine: MedlinePlus Medical Encyclopedia
Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase (Aminopeptidase B)-Like 1 (Rnpepl1)
Aminopeptidases | Profiles RNS
Streptococcus Lab: Id Strep Species General Methods Section 1 | CDC
and S - CDK4/6 Inhibitors in Bacterial Methionine Aminopeptidase Inhibition
Recent Progress of Activity-Based Fluorescent Probes for Imaging Leucine Aminopeptidase. | Biosensors (Basel);13(7)2023 Jul 21...
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of...
Definitions of neurotensin endopeptidase - OneLook Dictionary Search
Characterization of alanyl aminopeptidase from insecticide resistant and susceptible strains of <em>Musca domestica</em> L. -...
Table 1 - Animal Reservoirs and Hosts for Emerging Alphacoronaviruses and Betacoronaviruses - Volume 27, Number 4-April 2021 -...
Publication : USDA ARS
Diagnosing Drug-induced Liver Injury by Multispectral Optoacoustic Tomography and Fluorescence Imaging Using a Leucine...
TPP1 gene: MedlinePlus Genetics
Publication Detail
NIOSHTIC-2 Search Results - Full View
SCOPe 2.08: Structural Classification of Proteins - extended
metabolic pathway of other amino acids - Ontology Report - Rat Genome Database
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical...
Absence of Liver Toxicity in Perampanel-Treated Subjects: Pooled results from partial seizure phase III perampanel clinical...
MBS9711459 | XPP1 Polyclonal Antibody | MyBiosource
Norman R. Watts, Ph.D. | About NIAMS | NIAMS
Biomarkers Search
Genetic characterization of a new Apis mellifera esterase
| Apidologie
YRC Public Data Repository - Protein Structure Prediction - Protein Overview
MeSH Browser
Leucine5
- Leucine aminopeptidase is a type of protein called an enzyme. (medlineplus.gov)
- Recent Progress of Activity-Based Fluorescent Probes for Imaging Leucine Aminopeptidase. (bvsalud.org)
- Leucine aminopeptidase (LAP) is an important protease that can specifically hydrolyze Leucine residues. (bvsalud.org)
- Herein, we report an activatable optoacoustic probe for imaging DILI through detecting the activity of leucine aminopeptidase (LAP). (ithera-medical.com)
- 6. Novel leucine ureido derivatives as aminopeptidase N inhibitors. (nih.gov)
Methionine4
- 4. Synthesis, anticancer activity, and molecular modeling of etodolac-thioether derivatives as potent methionine aminopeptidase (type II) inhibitors. (nih.gov)
- 9. Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors. (nih.gov)
- An antiangiogenesis factor consisting of an antibiotic derived from Aspergillus fumigatus that exerts its effect by binding to the metalloprotease methionine aminopeptidase type 2. (medscape.com)
- In 2001, a TPD chimera called protac-1 was shown to be capable of degrading a target protein, methionine aminopeptidase-2, opening up the possibility of leveraging this approach against other protein targets involved in disease conditions. (nih.gov)
Inhibitors10
- The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NF?B signalling pathway. (uams.edu)
- 1. Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies. (nih.gov)
- 2. Highly functionalized tetrahydropyridines are cytotoxic and selective inhibitors of human puromycin sensitive aminopeptidase. (nih.gov)
- 3. Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3H)-quinazolinedione skeleton. (nih.gov)
- 10. Positioning of aminopeptidase inhibitors in next generation cancer therapy. (nih.gov)
- 11. Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. (nih.gov)
- 12. Enkephalin degradation in the guinea-pig ileum: effect of aminopeptidase inhibitors, puromycin and bestatin. (nih.gov)
- 14. [Preparation of novel specific aminopeptidase inhibitors with a cyclic imide skeleton]. (nih.gov)
- 15. Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA). (nih.gov)
- 17. Rapid and efficient synthesis of a novel series of substituted aminobenzosuberone derivatives as potent, selective, non-peptidic neutral aminopeptidase inhibitors. (nih.gov)
Alanine1
- The authors conclude that a significant risk of overexposure to cadmium dust did exist at this facility and that subclinical effects such as significant increases in mean levels of urinary tubular enzymes alanine-aminopeptidase and N-acetyl- glucosaminidase are apparent in cadmium exposed workers with urine cadmium levels above 10microg/g of creatinine compared to those below this level. (cdc.gov)
Alanyl1
- Characterization of alanyl aminopeptidase from insecticide resistant and susceptible strains of Musca domestica L. (ncl.ac.uk)
Inhibition1
- 7. Inhibition of aminopeptidase and acetylcholinesterase by puromycin and puromycin analogs. (nih.gov)
CD132
- Functional application: The antibody WM15 inhibits infection of cells by human coronavirus and inhibits aminopeptidase N activity of the CD13 molecule immunoprecipitates. (exbio.cz)
- CD13 (aminopeptidase N, APN) is a 150 kDa type II transmembrane zinc-binding ectopeptidase expressed on various cell types. (exbio.cz)
Protein1
- A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet's disease in HLA-B*51 carriers. (nih.gov)
Inhibitor2
- 5. CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. (nih.gov)
- 8. Specific inhibitor of puromycin-sensitive aminopeptidase with a homophthalimide skeleton: identification of the target molecule and a structure-activity relationship study. (nih.gov)
Membrane1
- 16. Comparison of the soluble and membrane-bound forms of the puromycin-sensitive enkephalin-degrading aminopeptidases from rat. (nih.gov)
Descriptor1
- Aminopeptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (uams.edu)
Human1
- This group of metallopeptidases belong to the MEROPS peptidase family M1 (clan MA(E)), the type example being aminopeptidase N from Homo sapiens (Human). (embl.de)
Activity1
- aminopeptidase-N): predominant functional activity in blood is localized to plasma and is not cell-surface associated. (exbio.cz)
Leucine aminopeptidase3
- Leucine aminopeptidase is a type of protein called an enzyme. (medlineplus.gov)
- The leucine aminopeptidase (LAP) test measures how much of this enzyme is in your blood. (nih.gov)
- Leucine aminopeptidase (LAP) is a proteolytic enzyme that breaks chemical bonds in proteins at specific sites next to leucine amino acids. (nih.gov)
Inhibitor4
- Fifty-two of the patients were tested for genetic variants in factor XII, plasminogen-activator inhibitor-1 (PAI-1), ACE, and aminopeptidase P (APP). (cdc.gov)
- 2. Specific inhibitor of puromycin-sensitive aminopeptidase with a homophthalimide skeleton: identification of the target molecule and a structure-activity relationship study. (nih.gov)
- 11. Inhibition of fiber cell globulization and hyperglycemia-induced lens opacification by aminopeptidase inhibitor bestatin. (nih.gov)
- 20. A derivative of aminopeptidase inhibitor (BE15) has a dual inhibitory effect of invasion and motility on tumor and endothelial cells. (nih.gov)
Endoplasmic reticulum5
- Endoplasmic reticulum aminopeptidases ERAP1 and ERAP2 have recently emerged as important players in regulating innate and adaptive immune responses by trimming peptide ligands for MHC class I molecules. (nih.gov)
- Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum. (nih.gov)
- On the other hand, variants of endoplasmic reticulum aminopeptidase 1 (ERAP1) are associated with several HLA class I-linked inflammatory diseases. (nih.gov)
- Endoplasmic reticulum aminopeptidase 1 (ERAP1) is part of the machinery in the endoplasmic reticulum that controls the processing of antigens to be presented on the cell surface within HLA class I protein molecules. (nih.gov)
- Paradoxical Effects of Endoplasmic Reticulum Aminopeptidase 1 Deficiency on HLA-B27 and Its Role as an Epistatic Modifier in Experimental Spondyloarthritis. (nih.gov)
Enzyme1
- 19. A specific enzyme assay for aminopeptidase M in rat brain. (nih.gov)
Inhibitors11
- In this chapter, we describe two basic methods for monitoring peptide-trimming activity by ER aminopeptidases and screening potential chemical inhibitors. (nih.gov)
- 1. [Preparation of novel specific aminopeptidase inhibitors with a cyclic imide skeleton]. (nih.gov)
- 3. Novel small molecule nonpeptide aminopeptidase n inhibitors with a cyclic imide skeleton. (nih.gov)
- 5. Specific nonpeptide inhibitors of puromycin-sensitive aminopeptidase with a 2,4(1H,3H)-quinazolinedione skeleton. (nih.gov)
- 7. Puromycin based inhibitors of aminopeptidases for the potential treatment of hematologic malignancies. (nih.gov)
- 8. Augmentation of death ligand-induced apoptosis by aminopeptidase inhibitors in human solid tumor cell lines. (nih.gov)
- 9. Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA). (nih.gov)
- 12. Inhibition of tumor cell invasion and matrix degradation by aminopeptidase inhibitors. (nih.gov)
- 16. Positioning of aminopeptidase inhibitors in next generation cancer therapy. (nih.gov)
- 17. Characterization of aminopeptidases responsible for inactivating endogenous (Met5)enkephalin in brain slices using peptidase inhibitors and anti-aminopeptidase M antibodies. (nih.gov)
- 18. Novel cyclic-imide peptidomimetics as aminopeptidase N inhibitors. (nih.gov)
Enzymes1
- Sequence comparisons with known enzymes of this class showed that CD13 and aminopeptidase N are identical. (nih.gov)
Small2
- Aminopeptidase N is located in the small-intestinal and renal microvillar membrane, and also in other plasma membranes. (nih.gov)
- In the small intestine aminopeptidase N plays a role in the final digestion of peptides generated from hydrolysis of proteins by gastric and pancreatic proteases. (nih.gov)
Class1
- Trimming of MHC Class I Ligands by ERAP Aminopeptidases. (nih.gov)